nodes	percent_of_prediction	percent_of_DWPC	metapath
Rizatriptan—Almotriptan—CYP2E1—liver cancer	0.00845	0.4	CrCbGaD
Rizatriptan—Melatonin—ESR1—liver cancer	0.00704	0.333	CrCbGaD
Rizatriptan—Acute coronary syndrome—Sorafenib—liver cancer	0.00615	0.00755	CcSEcCtD
Rizatriptan—Myocardial infarction—Sorafenib—liver cancer	0.00612	0.00751	CcSEcCtD
Rizatriptan—Paralysis—Epirubicin—liver cancer	0.00593	0.00729	CcSEcCtD
Rizatriptan—Epistaxis—Sorafenib—liver cancer	0.00588	0.00723	CcSEcCtD
Rizatriptan—Parosmia—Doxorubicin—liver cancer	0.00588	0.00722	CcSEcCtD
Rizatriptan—Melatonin—CYP1A1—liver cancer	0.00563	0.267	CrCbGaD
Rizatriptan—Paralysis—Doxorubicin—liver cancer	0.00549	0.00674	CcSEcCtD
Rizatriptan—Hyperaesthesia—Epirubicin—liver cancer	0.00525	0.00645	CcSEcCtD
Rizatriptan—Tinnitus—Sorafenib—liver cancer	0.00522	0.00641	CcSEcCtD
Rizatriptan—Flushing—Sorafenib—liver cancer	0.0052	0.00638	CcSEcCtD
Rizatriptan—Angiopathy—Sorafenib—liver cancer	0.00508	0.00624	CcSEcCtD
Rizatriptan—Dysphonia—Epirubicin—liver cancer	0.00501	0.00615	CcSEcCtD
Rizatriptan—Arrhythmia—Sorafenib—liver cancer	0.005	0.00614	CcSEcCtD
Rizatriptan—Mental disorder—Sorafenib—liver cancer	0.00491	0.00603	CcSEcCtD
Rizatriptan—Erythema—Sorafenib—liver cancer	0.00488	0.00599	CcSEcCtD
Rizatriptan—Hyperaesthesia—Doxorubicin—liver cancer	0.00486	0.00597	CcSEcCtD
Rizatriptan—Dysgeusia—Sorafenib—liver cancer	0.00477	0.00586	CcSEcCtD
Rizatriptan—Cardiovascular disorder—Epirubicin—liver cancer	0.00469	0.00576	CcSEcCtD
Rizatriptan—Muscle spasms—Sorafenib—liver cancer	0.00469	0.00576	CcSEcCtD
Rizatriptan—Dysphonia—Doxorubicin—liver cancer	0.00464	0.00569	CcSEcCtD
Rizatriptan—Lacrimation increased—Epirubicin—liver cancer	0.00447	0.00549	CcSEcCtD
Rizatriptan—Angioedema—Sorafenib—liver cancer	0.00445	0.00547	CcSEcCtD
Rizatriptan—Syncope—Sorafenib—liver cancer	0.00437	0.00537	CcSEcCtD
Rizatriptan—Dysarthria—Epirubicin—liver cancer	0.00436	0.00535	CcSEcCtD
Rizatriptan—Cardiovascular disorder—Doxorubicin—liver cancer	0.00434	0.00533	CcSEcCtD
Rizatriptan—Loss of consciousness—Sorafenib—liver cancer	0.00429	0.00526	CcSEcCtD
Rizatriptan—Cough—Sorafenib—liver cancer	0.00425	0.00522	CcSEcCtD
Rizatriptan—Gait disturbance—Epirubicin—liver cancer	0.00422	0.00519	CcSEcCtD
Rizatriptan—Hypertension—Sorafenib—liver cancer	0.00421	0.00517	CcSEcCtD
Rizatriptan—Coordination abnormal—Epirubicin—liver cancer	0.0042	0.00515	CcSEcCtD
Rizatriptan—Musculoskeletal pain—Epirubicin—liver cancer	0.00417	0.00512	CcSEcCtD
Rizatriptan—Neck pain—Epirubicin—liver cancer	0.00417	0.00512	CcSEcCtD
Rizatriptan—Arthralgia—Sorafenib—liver cancer	0.00415	0.0051	CcSEcCtD
Rizatriptan—Myalgia—Sorafenib—liver cancer	0.00415	0.0051	CcSEcCtD
Rizatriptan—Lacrimation increased—Doxorubicin—liver cancer	0.00414	0.00508	CcSEcCtD
Rizatriptan—Ventricular tachycardia—Epirubicin—liver cancer	0.00412	0.00506	CcSEcCtD
Rizatriptan—Hiccups—Epirubicin—liver cancer	0.00412	0.00506	CcSEcCtD
Rizatriptan—Dry mouth—Sorafenib—liver cancer	0.00406	0.00499	CcSEcCtD
Rizatriptan—Eructation—Epirubicin—liver cancer	0.00405	0.00497	CcSEcCtD
Rizatriptan—Dysarthria—Doxorubicin—liver cancer	0.00403	0.00495	CcSEcCtD
Rizatriptan—Anaphylactic shock—Sorafenib—liver cancer	0.00398	0.00489	CcSEcCtD
Rizatriptan—Shock—Sorafenib—liver cancer	0.00391	0.00481	CcSEcCtD
Rizatriptan—Gait disturbance—Doxorubicin—liver cancer	0.00391	0.0048	CcSEcCtD
Rizatriptan—Nervous system disorder—Sorafenib—liver cancer	0.0039	0.00479	CcSEcCtD
Rizatriptan—Coordination abnormal—Doxorubicin—liver cancer	0.00388	0.00477	CcSEcCtD
Rizatriptan—Musculoskeletal pain—Doxorubicin—liver cancer	0.00386	0.00474	CcSEcCtD
Rizatriptan—Neck pain—Doxorubicin—liver cancer	0.00386	0.00474	CcSEcCtD
Rizatriptan—Ventricular tachycardia—Doxorubicin—liver cancer	0.00381	0.00468	CcSEcCtD
Rizatriptan—Hiccups—Doxorubicin—liver cancer	0.00381	0.00468	CcSEcCtD
Rizatriptan—Dry eye—Epirubicin—liver cancer	0.00381	0.00468	CcSEcCtD
Rizatriptan—Anorexia—Sorafenib—liver cancer	0.00379	0.00466	CcSEcCtD
Rizatriptan—Eructation—Doxorubicin—liver cancer	0.00375	0.0046	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00363	0.00445	CcSEcCtD
Rizatriptan—Dyspnoea—Sorafenib—liver cancer	0.00355	0.00436	CcSEcCtD
Rizatriptan—Dry eye—Doxorubicin—liver cancer	0.00352	0.00433	CcSEcCtD
Rizatriptan—Dyspepsia—Sorafenib—liver cancer	0.0035	0.0043	CcSEcCtD
Rizatriptan—Decreased appetite—Sorafenib—liver cancer	0.00346	0.00425	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Sorafenib—liver cancer	0.00344	0.00422	CcSEcCtD
Rizatriptan—Fatigue—Sorafenib—liver cancer	0.00343	0.00421	CcSEcCtD
Rizatriptan—Photosensitivity—Epirubicin—liver cancer	0.00341	0.00418	CcSEcCtD
Rizatriptan—Constipation—Sorafenib—liver cancer	0.0034	0.00418	CcSEcCtD
Rizatriptan—Pain—Sorafenib—liver cancer	0.0034	0.00418	CcSEcCtD
Rizatriptan—Eye pain—Epirubicin—liver cancer	0.00331	0.00407	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Sorafenib—liver cancer	0.00325	0.004	CcSEcCtD
Rizatriptan—Hot flush—Epirubicin—liver cancer	0.0032	0.00393	CcSEcCtD
Rizatriptan—Increased appetite—Epirubicin—liver cancer	0.00318	0.00391	CcSEcCtD
Rizatriptan—Menopausal symptoms—Epirubicin—liver cancer	0.00317	0.00389	CcSEcCtD
Rizatriptan—Urticaria—Sorafenib—liver cancer	0.00316	0.00388	CcSEcCtD
Rizatriptan—Photosensitivity—Doxorubicin—liver cancer	0.00315	0.00387	CcSEcCtD
Rizatriptan—Abdominal pain—Sorafenib—liver cancer	0.00315	0.00386	CcSEcCtD
Rizatriptan—Body temperature increased—Sorafenib—liver cancer	0.00315	0.00386	CcSEcCtD
Rizatriptan—Anaphylactoid reaction—Epirubicin—liver cancer	0.00309	0.0038	CcSEcCtD
Rizatriptan—Eye pain—Doxorubicin—liver cancer	0.00307	0.00377	CcSEcCtD
Rizatriptan—Cerebrovascular accident—Epirubicin—liver cancer	0.00305	0.00375	CcSEcCtD
Rizatriptan—Osteoarthritis—Epirubicin—liver cancer	0.00299	0.00367	CcSEcCtD
Rizatriptan—Hot flush—Doxorubicin—liver cancer	0.00296	0.00363	CcSEcCtD
Rizatriptan—Increased appetite—Doxorubicin—liver cancer	0.00295	0.00362	CcSEcCtD
Rizatriptan—Menopausal symptoms—Doxorubicin—liver cancer	0.00293	0.0036	CcSEcCtD
Rizatriptan—Hypersensitivity—Sorafenib—liver cancer	0.00293	0.0036	CcSEcCtD
Rizatriptan—Face oedema—Epirubicin—liver cancer	0.00289	0.00355	CcSEcCtD
Rizatriptan—Anaphylactoid reaction—Doxorubicin—liver cancer	0.00286	0.00351	CcSEcCtD
Rizatriptan—Asthenia—Sorafenib—liver cancer	0.00285	0.00351	CcSEcCtD
Rizatriptan—Cerebrovascular accident—Doxorubicin—liver cancer	0.00282	0.00347	CcSEcCtD
Rizatriptan—Pruritus—Sorafenib—liver cancer	0.00282	0.00346	CcSEcCtD
Rizatriptan—Ataxia—Epirubicin—liver cancer	0.00281	0.00345	CcSEcCtD
Rizatriptan—Dehydration—Epirubicin—liver cancer	0.00278	0.00342	CcSEcCtD
Rizatriptan—Osteoarthritis—Doxorubicin—liver cancer	0.00277	0.0034	CcSEcCtD
Rizatriptan—Diarrhoea—Sorafenib—liver cancer	0.00272	0.00334	CcSEcCtD
Rizatriptan—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00269	0.00331	CcSEcCtD
Rizatriptan—Nasopharyngitis—Epirubicin—liver cancer	0.00268	0.00329	CcSEcCtD
Rizatriptan—Face oedema—Doxorubicin—liver cancer	0.00267	0.00328	CcSEcCtD
Rizatriptan—Gastritis—Epirubicin—liver cancer	0.00265	0.00325	CcSEcCtD
Rizatriptan—Muscular weakness—Epirubicin—liver cancer	0.00264	0.00324	CcSEcCtD
Rizatriptan—Dizziness—Sorafenib—liver cancer	0.00263	0.00323	CcSEcCtD
Rizatriptan—Abdominal distension—Epirubicin—liver cancer	0.0026	0.0032	CcSEcCtD
Rizatriptan—Ataxia—Doxorubicin—liver cancer	0.0026	0.0032	CcSEcCtD
Rizatriptan—Dysphagia—Epirubicin—liver cancer	0.00259	0.00318	CcSEcCtD
Rizatriptan—Dehydration—Doxorubicin—liver cancer	0.00257	0.00316	CcSEcCtD
Rizatriptan—Vomiting—Sorafenib—liver cancer	0.00253	0.00311	CcSEcCtD
Rizatriptan—Angina pectoris—Epirubicin—liver cancer	0.00252	0.00309	CcSEcCtD
Rizatriptan—Rash—Sorafenib—liver cancer	0.00251	0.00308	CcSEcCtD
Rizatriptan—Dermatitis—Sorafenib—liver cancer	0.00251	0.00308	CcSEcCtD
Rizatriptan—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00249	0.00306	CcSEcCtD
Rizatriptan—Headache—Sorafenib—liver cancer	0.00249	0.00306	CcSEcCtD
Rizatriptan—Nasopharyngitis—Doxorubicin—liver cancer	0.00248	0.00304	CcSEcCtD
Rizatriptan—Gastritis—Doxorubicin—liver cancer	0.00245	0.00301	CcSEcCtD
Rizatriptan—Muscular weakness—Doxorubicin—liver cancer	0.00244	0.003	CcSEcCtD
Rizatriptan—Dysuria—Epirubicin—liver cancer	0.00242	0.00297	CcSEcCtD
Rizatriptan—Abdominal distension—Doxorubicin—liver cancer	0.00241	0.00296	CcSEcCtD
Rizatriptan—Upper respiratory tract infection—Epirubicin—liver cancer	0.0024	0.00295	CcSEcCtD
Rizatriptan—Dysphagia—Doxorubicin—liver cancer	0.00239	0.00294	CcSEcCtD
Rizatriptan—Pollakiuria—Epirubicin—liver cancer	0.00239	0.00293	CcSEcCtD
Rizatriptan—Nausea—Sorafenib—liver cancer	0.00236	0.0029	CcSEcCtD
Rizatriptan—Photosensitivity reaction—Epirubicin—liver cancer	0.00236	0.0029	CcSEcCtD
Rizatriptan—Angina pectoris—Doxorubicin—liver cancer	0.00233	0.00286	CcSEcCtD
Rizatriptan—Dysuria—Doxorubicin—liver cancer	0.00224	0.00275	CcSEcCtD
Rizatriptan—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00222	0.00273	CcSEcCtD
Rizatriptan—Sweating—Epirubicin—liver cancer	0.00221	0.00271	CcSEcCtD
Rizatriptan—Pollakiuria—Doxorubicin—liver cancer	0.00221	0.00271	CcSEcCtD
Rizatriptan—Photosensitivity reaction—Doxorubicin—liver cancer	0.00218	0.00268	CcSEcCtD
Rizatriptan—Epistaxis—Epirubicin—liver cancer	0.00217	0.00267	CcSEcCtD
Rizatriptan—Bradycardia—Epirubicin—liver cancer	0.00211	0.00259	CcSEcCtD
Rizatriptan—Hypoaesthesia—Epirubicin—liver cancer	0.00206	0.00253	CcSEcCtD
Rizatriptan—Pharyngitis—Epirubicin—liver cancer	0.00205	0.00252	CcSEcCtD
Rizatriptan—Sweating—Doxorubicin—liver cancer	0.00205	0.00251	CcSEcCtD
Rizatriptan—Epistaxis—Doxorubicin—liver cancer	0.00201	0.00247	CcSEcCtD
Rizatriptan—Bradycardia—Doxorubicin—liver cancer	0.00195	0.00239	CcSEcCtD
Rizatriptan—Tinnitus—Epirubicin—liver cancer	0.00193	0.00237	CcSEcCtD
Rizatriptan—Flushing—Epirubicin—liver cancer	0.00192	0.00236	CcSEcCtD
Rizatriptan—Hypoaesthesia—Doxorubicin—liver cancer	0.00191	0.00234	CcSEcCtD
Rizatriptan—Pharyngitis—Doxorubicin—liver cancer	0.0019	0.00233	CcSEcCtD
Rizatriptan—Angiopathy—Epirubicin—liver cancer	0.00188	0.00231	CcSEcCtD
Rizatriptan—Chills—Epirubicin—liver cancer	0.00186	0.00228	CcSEcCtD
Rizatriptan—Arrhythmia—Epirubicin—liver cancer	0.00185	0.00227	CcSEcCtD
Rizatriptan—Mental disorder—Epirubicin—liver cancer	0.00181	0.00223	CcSEcCtD
Rizatriptan—Erythema—Epirubicin—liver cancer	0.0018	0.00221	CcSEcCtD
Rizatriptan—Tinnitus—Doxorubicin—liver cancer	0.00179	0.00219	CcSEcCtD
Rizatriptan—Flushing—Doxorubicin—liver cancer	0.00178	0.00218	CcSEcCtD
Rizatriptan—Flatulence—Epirubicin—liver cancer	0.00178	0.00218	CcSEcCtD
Rizatriptan—Tension—Epirubicin—liver cancer	0.00177	0.00217	CcSEcCtD
Rizatriptan—Dysgeusia—Epirubicin—liver cancer	0.00176	0.00217	CcSEcCtD
Rizatriptan—Nervousness—Epirubicin—liver cancer	0.00175	0.00215	CcSEcCtD
Rizatriptan—Angiopathy—Doxorubicin—liver cancer	0.00174	0.00213	CcSEcCtD
Rizatriptan—Muscle spasms—Epirubicin—liver cancer	0.00173	0.00213	CcSEcCtD
Rizatriptan—Chills—Doxorubicin—liver cancer	0.00172	0.00211	CcSEcCtD
Rizatriptan—Arrhythmia—Doxorubicin—liver cancer	0.00171	0.0021	CcSEcCtD
Rizatriptan—Vision blurred—Epirubicin—liver cancer	0.0017	0.00209	CcSEcCtD
Rizatriptan—Mental disorder—Doxorubicin—liver cancer	0.00168	0.00206	CcSEcCtD
Rizatriptan—Erythema—Doxorubicin—liver cancer	0.00167	0.00205	CcSEcCtD
Rizatriptan—Agitation—Epirubicin—liver cancer	0.00166	0.00203	CcSEcCtD
Rizatriptan—Flatulence—Doxorubicin—liver cancer	0.00164	0.00202	CcSEcCtD
Rizatriptan—Tension—Doxorubicin—liver cancer	0.00164	0.00201	CcSEcCtD
Rizatriptan—Dysgeusia—Doxorubicin—liver cancer	0.00163	0.002	CcSEcCtD
Rizatriptan—Nervousness—Doxorubicin—liver cancer	0.00162	0.00199	CcSEcCtD
Rizatriptan—Vertigo—Epirubicin—liver cancer	0.00162	0.00199	CcSEcCtD
Rizatriptan—Syncope—Epirubicin—liver cancer	0.00162	0.00198	CcSEcCtD
Rizatriptan—Muscle spasms—Doxorubicin—liver cancer	0.0016	0.00197	CcSEcCtD
Rizatriptan—Palpitations—Epirubicin—liver cancer	0.00159	0.00196	CcSEcCtD
Rizatriptan—Loss of consciousness—Epirubicin—liver cancer	0.00158	0.00194	CcSEcCtD
Rizatriptan—Cough—Epirubicin—liver cancer	0.00157	0.00193	CcSEcCtD
Rizatriptan—Vision blurred—Doxorubicin—liver cancer	0.00157	0.00193	CcSEcCtD
Rizatriptan—Convulsion—Epirubicin—liver cancer	0.00156	0.00192	CcSEcCtD
Rizatriptan—Hypertension—Epirubicin—liver cancer	0.00156	0.00191	CcSEcCtD
Rizatriptan—Myalgia—Epirubicin—liver cancer	0.00153	0.00188	CcSEcCtD
Rizatriptan—Arthralgia—Epirubicin—liver cancer	0.00153	0.00188	CcSEcCtD
Rizatriptan—Chest pain—Epirubicin—liver cancer	0.00153	0.00188	CcSEcCtD
Rizatriptan—Agitation—Doxorubicin—liver cancer	0.00153	0.00188	CcSEcCtD
Rizatriptan—Anxiety—Epirubicin—liver cancer	0.00153	0.00188	CcSEcCtD
Rizatriptan—Discomfort—Epirubicin—liver cancer	0.00152	0.00186	CcSEcCtD
Rizatriptan—Dry mouth—Epirubicin—liver cancer	0.0015	0.00184	CcSEcCtD
Rizatriptan—Vertigo—Doxorubicin—liver cancer	0.0015	0.00184	CcSEcCtD
Rizatriptan—Syncope—Doxorubicin—liver cancer	0.0015	0.00184	CcSEcCtD
Rizatriptan—Confusional state—Epirubicin—liver cancer	0.00148	0.00182	CcSEcCtD
Rizatriptan—Palpitations—Doxorubicin—liver cancer	0.00147	0.00181	CcSEcCtD
Rizatriptan—Anaphylactic shock—Epirubicin—liver cancer	0.00147	0.00181	CcSEcCtD
Rizatriptan—Oedema—Epirubicin—liver cancer	0.00147	0.00181	CcSEcCtD
Rizatriptan—Loss of consciousness—Doxorubicin—liver cancer	0.00147	0.0018	CcSEcCtD
Rizatriptan—Cough—Doxorubicin—liver cancer	0.00145	0.00179	CcSEcCtD
Rizatriptan—Shock—Epirubicin—liver cancer	0.00145	0.00178	CcSEcCtD
Rizatriptan—Convulsion—Doxorubicin—liver cancer	0.00144	0.00177	CcSEcCtD
Rizatriptan—Nervous system disorder—Epirubicin—liver cancer	0.00144	0.00177	CcSEcCtD
Rizatriptan—Hypertension—Doxorubicin—liver cancer	0.00144	0.00177	CcSEcCtD
Rizatriptan—Tachycardia—Epirubicin—liver cancer	0.00144	0.00176	CcSEcCtD
Rizatriptan—Hyperhidrosis—Epirubicin—liver cancer	0.00142	0.00175	CcSEcCtD
Rizatriptan—Arthralgia—Doxorubicin—liver cancer	0.00142	0.00174	CcSEcCtD
Rizatriptan—Chest pain—Doxorubicin—liver cancer	0.00142	0.00174	CcSEcCtD
Rizatriptan—Myalgia—Doxorubicin—liver cancer	0.00142	0.00174	CcSEcCtD
Rizatriptan—Anxiety—Doxorubicin—liver cancer	0.00141	0.00174	CcSEcCtD
Rizatriptan—Discomfort—Doxorubicin—liver cancer	0.0014	0.00172	CcSEcCtD
Rizatriptan—Anorexia—Epirubicin—liver cancer	0.0014	0.00172	CcSEcCtD
Rizatriptan—Dry mouth—Doxorubicin—liver cancer	0.00139	0.0017	CcSEcCtD
Rizatriptan—Confusional state—Doxorubicin—liver cancer	0.00137	0.00168	CcSEcCtD
Rizatriptan—Anaphylactic shock—Doxorubicin—liver cancer	0.00136	0.00167	CcSEcCtD
Rizatriptan—Oedema—Doxorubicin—liver cancer	0.00136	0.00167	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00134	0.00165	CcSEcCtD
Rizatriptan—Shock—Doxorubicin—liver cancer	0.00134	0.00164	CcSEcCtD
Rizatriptan—Nervous system disorder—Doxorubicin—liver cancer	0.00133	0.00164	CcSEcCtD
Rizatriptan—Insomnia—Epirubicin—liver cancer	0.00133	0.00163	CcSEcCtD
Rizatriptan—Tachycardia—Doxorubicin—liver cancer	0.00133	0.00163	CcSEcCtD
Rizatriptan—Paraesthesia—Epirubicin—liver cancer	0.00132	0.00162	CcSEcCtD
Rizatriptan—Hyperhidrosis—Doxorubicin—liver cancer	0.00132	0.00162	CcSEcCtD
Rizatriptan—Dyspnoea—Epirubicin—liver cancer	0.00131	0.00161	CcSEcCtD
Rizatriptan—Somnolence—Epirubicin—liver cancer	0.00131	0.00161	CcSEcCtD
Rizatriptan—Anorexia—Doxorubicin—liver cancer	0.0013	0.00159	CcSEcCtD
Rizatriptan—Dyspepsia—Epirubicin—liver cancer	0.00129	0.00159	CcSEcCtD
Rizatriptan—Decreased appetite—Epirubicin—liver cancer	0.00128	0.00157	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Epirubicin—liver cancer	0.00127	0.00156	CcSEcCtD
Rizatriptan—Fatigue—Epirubicin—liver cancer	0.00127	0.00156	CcSEcCtD
Rizatriptan—Constipation—Epirubicin—liver cancer	0.00126	0.00154	CcSEcCtD
Rizatriptan—Pain—Epirubicin—liver cancer	0.00126	0.00154	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00124	0.00152	CcSEcCtD
Rizatriptan—Insomnia—Doxorubicin—liver cancer	0.00123	0.00151	CcSEcCtD
Rizatriptan—Paraesthesia—Doxorubicin—liver cancer	0.00122	0.0015	CcSEcCtD
Rizatriptan—Dyspnoea—Doxorubicin—liver cancer	0.00121	0.00149	CcSEcCtD
Rizatriptan—Feeling abnormal—Epirubicin—liver cancer	0.00121	0.00149	CcSEcCtD
Rizatriptan—Somnolence—Doxorubicin—liver cancer	0.00121	0.00149	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Epirubicin—liver cancer	0.0012	0.00148	CcSEcCtD
Rizatriptan—Dyspepsia—Doxorubicin—liver cancer	0.0012	0.00147	CcSEcCtD
Rizatriptan—Decreased appetite—Doxorubicin—liver cancer	0.00118	0.00145	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00117	0.00144	CcSEcCtD
Rizatriptan—Fatigue—Doxorubicin—liver cancer	0.00117	0.00144	CcSEcCtD
Rizatriptan—Urticaria—Epirubicin—liver cancer	0.00117	0.00143	CcSEcCtD
Rizatriptan—Pain—Doxorubicin—liver cancer	0.00116	0.00143	CcSEcCtD
Rizatriptan—Constipation—Doxorubicin—liver cancer	0.00116	0.00143	CcSEcCtD
Rizatriptan—Body temperature increased—Epirubicin—liver cancer	0.00116	0.00143	CcSEcCtD
Rizatriptan—Abdominal pain—Epirubicin—liver cancer	0.00116	0.00143	CcSEcCtD
Rizatriptan—Feeling abnormal—Doxorubicin—liver cancer	0.00112	0.00138	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Doxorubicin—liver cancer	0.00111	0.00137	CcSEcCtD
Rizatriptan—Hypersensitivity—Epirubicin—liver cancer	0.00108	0.00133	CcSEcCtD
Rizatriptan—Urticaria—Doxorubicin—liver cancer	0.00108	0.00133	CcSEcCtD
Rizatriptan—Abdominal pain—Doxorubicin—liver cancer	0.00108	0.00132	CcSEcCtD
Rizatriptan—Body temperature increased—Doxorubicin—liver cancer	0.00108	0.00132	CcSEcCtD
Rizatriptan—Asthenia—Epirubicin—liver cancer	0.00106	0.0013	CcSEcCtD
Rizatriptan—Pruritus—Epirubicin—liver cancer	0.00104	0.00128	CcSEcCtD
Rizatriptan—Diarrhoea—Epirubicin—liver cancer	0.00101	0.00124	CcSEcCtD
Rizatriptan—Hypersensitivity—Doxorubicin—liver cancer	0.001	0.00123	CcSEcCtD
Rizatriptan—Asthenia—Doxorubicin—liver cancer	0.000976	0.0012	CcSEcCtD
Rizatriptan—Dizziness—Epirubicin—liver cancer	0.000972	0.00119	CcSEcCtD
Rizatriptan—Pruritus—Doxorubicin—liver cancer	0.000963	0.00118	CcSEcCtD
Rizatriptan—Vomiting—Epirubicin—liver cancer	0.000935	0.00115	CcSEcCtD
Rizatriptan—Diarrhoea—Doxorubicin—liver cancer	0.000931	0.00114	CcSEcCtD
Rizatriptan—Rash—Epirubicin—liver cancer	0.000927	0.00114	CcSEcCtD
Rizatriptan—Dermatitis—Epirubicin—liver cancer	0.000926	0.00114	CcSEcCtD
Rizatriptan—Headache—Epirubicin—liver cancer	0.000921	0.00113	CcSEcCtD
Rizatriptan—Dizziness—Doxorubicin—liver cancer	0.0009	0.0011	CcSEcCtD
Rizatriptan—Nausea—Epirubicin—liver cancer	0.000873	0.00107	CcSEcCtD
Rizatriptan—Vomiting—Doxorubicin—liver cancer	0.000865	0.00106	CcSEcCtD
Rizatriptan—Rash—Doxorubicin—liver cancer	0.000858	0.00105	CcSEcCtD
Rizatriptan—Dermatitis—Doxorubicin—liver cancer	0.000857	0.00105	CcSEcCtD
Rizatriptan—Headache—Doxorubicin—liver cancer	0.000852	0.00105	CcSEcCtD
Rizatriptan—Nausea—Doxorubicin—liver cancer	0.000808	0.000993	CcSEcCtD
Rizatriptan—HTR1D—Signaling by GPCR—PIK3CG—liver cancer	0.000107	0.000651	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—MAPK14—liver cancer	0.000107	0.000649	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—CSF2—liver cancer	0.000106	0.000647	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—PIK3CG—liver cancer	0.000105	0.000638	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—ESR1—liver cancer	0.000105	0.000636	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—PIK3CD—liver cancer	0.000104	0.000631	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—F2—liver cancer	0.000103	0.000629	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—PIK3CD—liver cancer	0.000102	0.000617	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—PIK3CG—liver cancer	9.9e-05	0.000602	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—APC—liver cancer	9.9e-05	0.000602	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—ADAM17—liver cancer	9.76e-05	0.000593	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—GSTP1—liver cancer	9.74e-05	0.000592	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—HMOX1—liver cancer	9.61e-05	0.000584	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—PRKCE—liver cancer	9.53e-05	0.000579	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—PIK3CD—liver cancer	9.42e-05	0.000573	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—PRKCE—liver cancer	9.33e-05	0.000567	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—BRAF—liver cancer	9.31e-05	0.000566	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—PIK3CD—liver cancer	9.23e-05	0.000561	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—F2—liver cancer	9.2e-05	0.000559	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—PSMA4—liver cancer	9.18e-05	0.000558	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—PSMD10—liver cancer	9.18e-05	0.000558	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—PIK3CB—liver cancer	9.05e-05	0.00055	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—IGF2—liver cancer	9.03e-05	0.000549	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	8.98e-05	0.000546	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—GSTM1—liver cancer	8.95e-05	0.000544	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—PIK3CB—liver cancer	8.86e-05	0.000538	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—IGF2—liver cancer	8.84e-05	0.000537	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—PIK3CG—liver cancer	8.81e-05	0.000535	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—PIK3CD—liver cancer	8.71e-05	0.000529	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—PIK3CA—liver cancer	8.62e-05	0.000524	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—SERPINE1—liver cancer	8.61e-05	0.000523	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—KRAS—liver cancer	8.52e-05	0.000518	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—CYP1A1—liver cancer	8.49e-05	0.000515	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CSF2—liver cancer	8.43e-05	0.000512	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—RAF1—liver cancer	8.41e-05	0.000511	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—F2—liver cancer	8.36e-05	0.000508	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—H2AFX—liver cancer	8.31e-05	0.000505	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—IL2—liver cancer	8.31e-05	0.000505	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CPT1B—liver cancer	8.29e-05	0.000504	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GLUL—liver cancer	8.29e-05	0.000504	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CSF2—liver cancer	8.26e-05	0.000502	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—RAF1—liver cancer	8.24e-05	0.000501	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—PIK3CB—liver cancer	8.22e-05	0.000499	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—H2AFX—liver cancer	8.14e-05	0.000494	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—IL2—liver cancer	8.13e-05	0.000494	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—PIK3CB—liver cancer	8.04e-05	0.000489	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—PIK3CG—liver cancer	8e-05	0.000486	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—NR1H4—liver cancer	8e-05	0.000486	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—MTHFR—liver cancer	7.91e-05	0.000481	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GSTA3—liver cancer	7.86e-05	0.000478	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—PIK3CA—liver cancer	7.83e-05	0.000476	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—RAF1—liver cancer	7.77e-05	0.000472	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PPARA—liver cancer	7.76e-05	0.000471	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—PIK3CD—liver cancer	7.74e-05	0.00047	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—MTOR—liver cancer	7.59e-05	0.000461	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—PIK3CB—liver cancer	7.59e-05	0.000461	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—IL2—liver cancer	7.54e-05	0.000458	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—TERT—liver cancer	7.52e-05	0.000457	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—IL2—liver cancer	7.39e-05	0.000449	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—TERT—liver cancer	7.36e-05	0.000447	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—HRAS—liver cancer	7.25e-05	0.00044	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GSTA4—liver cancer	7.19e-05	0.000437	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CDKN1B—liver cancer	7.12e-05	0.000433	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—PRKCE—liver cancer	7.11e-05	0.000432	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—AKT1—liver cancer	7.04e-05	0.000428	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—PIK3CD—liver cancer	7.03e-05	0.000427	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	7.03e-05	0.000427	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GSTA2—liver cancer	7.01e-05	0.000426	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CASP3—liver cancer	6.98e-05	0.000424	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—IL2—liver cancer	6.97e-05	0.000423	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—IL6—liver cancer	6.93e-05	0.000421	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—KDR—liver cancer	6.88e-05	0.000418	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—MAPK14—liver cancer	6.83e-05	0.000415	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CCND1—liver cancer	6.79e-05	0.000413	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—JUN—liver cancer	6.78e-05	0.000412	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GSTA1—liver cancer	6.76e-05	0.000411	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—PIK3CB—liver cancer	6.75e-05	0.00041	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—IGF2—liver cancer	6.74e-05	0.000409	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—KDR—liver cancer	6.73e-05	0.000409	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CTNNB1—liver cancer	6.73e-05	0.000409	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—ESR1—liver cancer	6.7e-05	0.000407	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—MAPK14—liver cancer	6.69e-05	0.000406	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—NAT2—liver cancer	6.68e-05	0.000406	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PIK3CG—liver cancer	6.65e-05	0.000404	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—F2—liver cancer	6.62e-05	0.000402	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—MMP9—liver cancer	6.6e-05	0.000401	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CDKN1A—liver cancer	6.57e-05	0.000399	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—ESR1—liver cancer	6.56e-05	0.000399	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—F2—liver cancer	6.48e-05	0.000394	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	6.43e-05	0.00039	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—MAPK8—liver cancer	6.41e-05	0.00039	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PPARG—liver cancer	6.41e-05	0.00039	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—ALDOB—liver cancer	6.41e-05	0.000389	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—AKT1—liver cancer	6.4e-05	0.000389	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—PIK3CG—liver cancer	6.33e-05	0.000385	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—APC—liver cancer	6.33e-05	0.000385	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CSF2—liver cancer	6.29e-05	0.000382	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—RAF1—liver cancer	6.28e-05	0.000381	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—PIK3CG—liver cancer	6.2e-05	0.000377	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—APC—liver cancer	6.2e-05	0.000377	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—H2AFX—liver cancer	6.2e-05	0.000377	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—IL2—liver cancer	6.2e-05	0.000376	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—PIK3CB—liver cancer	6.13e-05	0.000372	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CRABP1—liver cancer	6.11e-05	0.000371	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—BRAF—liver cancer	5.95e-05	0.000362	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—VEGFA—liver cancer	5.92e-05	0.00036	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—STAT3—liver cancer	5.86e-05	0.000356	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PIK3CD—liver cancer	5.84e-05	0.000355	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—BRAF—liver cancer	5.83e-05	0.000354	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—ALB—liver cancer	5.77e-05	0.00035	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—IL2—liver cancer	5.63e-05	0.000342	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—TERT—liver cancer	5.61e-05	0.000341	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—PIK3CD—liver cancer	5.57e-05	0.000338	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—PIK3CA—liver cancer	5.51e-05	0.000335	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—SERPINE1—liver cancer	5.51e-05	0.000335	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	5.5e-05	0.000334	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—PIK3CD—liver cancer	5.45e-05	0.000331	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—KRAS—liver cancer	5.45e-05	0.000331	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—MYC—liver cancer	5.45e-05	0.000331	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—TGFB1—liver cancer	5.44e-05	0.00033	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—PIK3CA—liver cancer	5.4e-05	0.000328	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—SERPINE1—liver cancer	5.39e-05	0.000328	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—HPGDS—liver cancer	5.34e-05	0.000325	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—KRAS—liver cancer	5.34e-05	0.000324	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	5.31e-05	0.000323	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—KDR—liver cancer	5.13e-05	0.000312	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—MAPK14—liver cancer	5.09e-05	0.000309	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PIK3CB—liver cancer	5.09e-05	0.000309	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—KRAS—liver cancer	5.04e-05	0.000306	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—PIK3CA—liver cancer	5.01e-05	0.000304	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—ESR1—liver cancer	5e-05	0.000304	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—RAF1—liver cancer	4.97e-05	0.000302	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—F2—liver cancer	4.94e-05	0.0003	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—PIK3CA—liver cancer	4.9e-05	0.000298	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—RAF1—liver cancer	4.87e-05	0.000296	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—MTOR—liver cancer	4.85e-05	0.000295	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—PIK3CB—liver cancer	4.85e-05	0.000295	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.84e-05	0.000294	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.78e-05	0.00029	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PSMA4—liver cancer	4.76e-05	0.000289	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PSMD10—liver cancer	4.76e-05	0.000289	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—MTOR—liver cancer	4.75e-05	0.000289	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—PIK3CB—liver cancer	4.75e-05	0.000289	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—APC—liver cancer	4.72e-05	0.000287	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—PIK3CG—liver cancer	4.72e-05	0.000287	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—HRAS—liver cancer	4.63e-05	0.000281	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GOT2—liver cancer	4.63e-05	0.000281	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—PIK3CA—liver cancer	4.63e-05	0.000281	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CDKN1B—liver cancer	4.55e-05	0.000277	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—HRAS—liver cancer	4.54e-05	0.000276	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—AKT1—liver cancer	4.51e-05	0.000274	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—TP53—liver cancer	4.48e-05	0.000272	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CASP3—liver cancer	4.46e-05	0.000271	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CDKN1B—liver cancer	4.46e-05	0.000271	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—IL2—liver cancer	4.46e-05	0.000271	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—BRAF—liver cancer	4.44e-05	0.00027	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—IL6—liver cancer	4.43e-05	0.000269	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—AKT1—liver cancer	4.41e-05	0.000268	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CASP3—liver cancer	4.37e-05	0.000266	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—IL2—liver cancer	4.36e-05	0.000265	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CYP2E1—liver cancer	4.36e-05	0.000265	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CCND1—liver cancer	4.34e-05	0.000264	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—IL6—liver cancer	4.34e-05	0.000264	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—JUN—liver cancer	4.34e-05	0.000263	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CTNNB1—liver cancer	4.3e-05	0.000261	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—HRAS—liver cancer	4.28e-05	0.00026	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CCND1—liver cancer	4.25e-05	0.000258	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—JUN—liver cancer	4.25e-05	0.000258	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—MMP9—liver cancer	4.22e-05	0.000256	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.22e-05	0.000256	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CTNNB1—liver cancer	4.21e-05	0.000256	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CDKN1A—liver cancer	4.2e-05	0.000255	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—PIK3CD—liver cancer	4.15e-05	0.000252	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—MMP9—liver cancer	4.13e-05	0.000251	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CDKN1A—liver cancer	4.12e-05	0.00025	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—PIK3CA—liver cancer	4.11e-05	0.00025	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—SERPINE1—liver cancer	4.11e-05	0.00025	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—MAPK8—liver cancer	4.1e-05	0.000249	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—IL6—liver cancer	4.1e-05	0.000249	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—AKT1—liver cancer	4.09e-05	0.000249	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CYCS—liver cancer	4.08e-05	0.000248	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—KRAS—liver cancer	4.07e-05	0.000247	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—MAPK8—liver cancer	4.02e-05	0.000244	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—AKT1—liver cancer	4.01e-05	0.000243	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GGT1—liver cancer	4e-05	0.000243	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GOT1—liver cancer	4e-05	0.000243	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—VEGFA—liver cancer	3.79e-05	0.00023	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—AKT1—liver cancer	3.78e-05	0.00023	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—STAT3—liver cancer	3.75e-05	0.000228	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—PIK3CA—liver cancer	3.74e-05	0.000227	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—VEGFA—liver cancer	3.71e-05	0.000225	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—RAF1—liver cancer	3.71e-05	0.000225	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—STAT3—liver cancer	3.67e-05	0.000223	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—PIK3CB—liver cancer	3.62e-05	0.00022	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—MTOR—liver cancer	3.62e-05	0.00022	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GSTP1—liver cancer	3.59e-05	0.000218	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—HMOX1—liver cancer	3.54e-05	0.000215	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—MYC—liver cancer	3.48e-05	0.000212	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—TGFB1—liver cancer	3.48e-05	0.000211	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—HRAS—liver cancer	3.46e-05	0.00021	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—MYC—liver cancer	3.41e-05	0.000207	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—TGFB1—liver cancer	3.4e-05	0.000207	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CDKN1B—liver cancer	3.4e-05	0.000206	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—AKT1—liver cancer	3.36e-05	0.000204	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CASP3—liver cancer	3.33e-05	0.000202	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—IL2—liver cancer	3.32e-05	0.000202	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—IL6—liver cancer	3.31e-05	0.000201	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GSTM1—liver cancer	3.3e-05	0.000201	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CCND1—liver cancer	3.24e-05	0.000197	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—JUN—liver cancer	3.23e-05	0.000196	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—KRAS—liver cancer	3.22e-05	0.000196	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CTNNB1—liver cancer	3.21e-05	0.000195	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—KRAS—liver cancer	3.15e-05	0.000192	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—MMP9—liver cancer	3.15e-05	0.000191	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CDKN1A—liver cancer	3.14e-05	0.00019	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CYP1A1—liver cancer	3.13e-05	0.00019	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PIK3CA—liver cancer	3.1e-05	0.000189	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—MAPK8—liver cancer	3.06e-05	0.000186	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—AKT1—liver cancer	3.05e-05	0.000185	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—PIK3CA—liver cancer	2.96e-05	0.00018	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—MTHFR—liver cancer	2.92e-05	0.000177	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—PIK3CA—liver cancer	2.9e-05	0.000176	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PPARA—liver cancer	2.86e-05	0.000174	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—TP53—liver cancer	2.86e-05	0.000174	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—VEGFA—liver cancer	2.83e-05	0.000172	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—TP53—liver cancer	2.8e-05	0.00017	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—STAT3—liver cancer	2.8e-05	0.00017	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—HRAS—liver cancer	2.74e-05	0.000166	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—HRAS—liver cancer	2.68e-05	0.000163	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—IL6—liver cancer	2.62e-05	0.000159	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—MYC—liver cancer	2.6e-05	0.000158	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—TGFB1—liver cancer	2.59e-05	0.000158	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.57e-05	0.000156	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—IL6—liver cancer	2.57e-05	0.000156	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—AKT1—liver cancer	2.54e-05	0.000154	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PIK3CG—liver cancer	2.45e-05	0.000149	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—AKT1—liver cancer	2.42e-05	0.000147	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—KRAS—liver cancer	2.4e-05	0.000146	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—AKT1—liver cancer	2.37e-05	0.000144	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PPARG—liver cancer	2.37e-05	0.000144	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—PIK3CA—liver cancer	2.21e-05	0.000134	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PIK3CD—liver cancer	2.15e-05	0.000131	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—TP53—liver cancer	2.13e-05	0.00013	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—ALB—liver cancer	2.13e-05	0.000129	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—HRAS—liver cancer	2.04e-05	0.000124	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—IL6—liver cancer	1.95e-05	0.000119	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PIK3CB—liver cancer	1.88e-05	0.000114	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—AKT1—liver cancer	1.8e-05	0.00011	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PIK3CA—liver cancer	1.14e-05	6.96e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—AKT1—liver cancer	9.35e-06	5.68e-05	CbGpPWpGaD
